Literature DB >> 19190230

Evaluation of interferences between dengue vaccine serotypes in a monkey model.

Bruno Guy1, Veronique Barban, Nathalie Mantel, Marion Aguirre, Sandrine Gulia, Jeremy Pontvianne, Therese-Marie Jourdier, Laurence Ramirez, Veronique Gregoire, Christophe Charnay, Nicolas Burdin, Rafaele Dumas, Jean Lang.   

Abstract

Interferences between different antigens in the same vaccine formulation have been reported for some vaccines (e.g., polio vaccines, live attenuated dengue vaccine candidates). We examined interferences between the four serotypes of ChimeriVax dengue vaccines (CYDs) in a monkey model when present within a tetravalent formulation in equal concentrations (TV-5555). Immunoassays of vaccinated non-human primates showed that serotype 4 (DEN-4), and to a lesser extent, DEN-1 were dominant in terms of neutralizing antibody levels. Parameters that affected the interferences were identified, including 1) the simultaneous administration of two complementary bivalent vaccines at separate anatomical sites drained by different lymph nodes; 2) the sequential administration of two complementary bivalent vaccines; 3) the establishment of heterologous flavivirus pre-immunity before subsequent tetravalent immunization; 4) the adaptation of formulations by decreasing the dose of the immunodominant serotype; and 5) the administration of a 1-year booster. The applicability of these data to human responses is discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19190230

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  54 in total

1.  Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.

Authors:  J Brian Kimble; Delphine C Malherbe; Michelle Meyer; Bronwyn M Gunn; Marcus M Karim; Philipp A Ilinykh; Mathieu Iampietro; Khaled S Mohamed; Surendra Negi; Pavlo Gilchuk; Kai Huang; Yuri I Wolf; Werner Braun; James E Crowe; Galit Alter; Alexander Bukreyev
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

2.  Sequential immunization with heterologous chimeric flaviviruses induces broad-spectrum cross-reactive CD8+ T cell responses.

Authors:  Rekha Singh; Alan L Rothman; James Potts; Farshad Guirakhoo; Francis A Ennis; Sharone Green
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

3.  The necessity and quandaries of dengue vaccine development.

Authors:  Stephen J Thomas
Journal:  J Infect Dis       Date:  2011-02-01       Impact factor: 5.226

4.  Antiviral activity of chloroquine against dengue virus type 2 replication in Aotus monkeys.

Authors:  Kleber Juvenal Silva Farias; Paula Renata Lima Machado; José Augusto Pereira Carneiro Muniz; Aline Amaral Imbeloni; Benedito Antônio Lopes da Fonseca
Journal:  Viral Immunol       Date:  2015-02-09       Impact factor: 2.257

Review 5.  How innate immune mechanisms contribute to antibody-enhanced viral infections.

Authors:  Sukathida Ubol; Scott B Halstead
Journal:  Clin Vaccine Immunol       Date:  2010-09-28

6.  Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques.

Authors:  Jorge E Osorio; Joseph N Brewoo; Shawn J Silengo; John Arguello; Ioana R Moldovan; Magdalena Tary-Lehmann; Tim D Powell; Jill A Livengood; Richard M Kinney; Claire Y-H Huang; Dan T Stinchcomb
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

7.  An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.

Authors:  Akane Urakami; Mya Myat Ngwe Tun; Meng Ling Moi; Atsuko Sakurai; Momoko Ishikawa; Sachiko Kuno; Ryuji Ueno; Kouichi Morita; Wataru Akahata
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

Review 8.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? Questions Raised by the Development and Implementation of Dengue Vaccines: Example of the Sanofi Pasteur Tetravalent Dengue Vaccine.

Authors:  Bruno Guy
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

9.  An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection.

Authors:  Laura J White; Carlos A Sariol; Melissa D Mattocks; Wahala Wahala M P B; Vorraphun Yingsiwaphat; Martha L Collier; Jill Whitley; Rochelle Mikkelsen; Idia V Rodriguez; Melween I Martinez; Aravinda de Silva; Robert E Johnston
Journal:  J Virol       Date:  2013-01-09       Impact factor: 5.103

10.  A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.

Authors:  Anna P Durbin; Beth D Kirkpatrick; Kristen K Pierce; Daniel Elwood; Catherine J Larsson; Janet C Lindow; Cecilia Tibery; Beulah P Sabundayo; Donna Shaffer; Kawsar R Talaat; Noreen A Hynes; Kimberli Wanionek; Marya P Carmolli; Catherine J Luke; Brian R Murphy; Kanta Subbarao; Stephen S Whitehead
Journal:  J Infect Dis       Date:  2013-01-17       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.